Prophylaxis Of Nephropathy > AVERT
~47 spots leftby Apr 2026

AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN

(AVERT™ Trial)

Recruiting in Palo Alto (17 mi)
+38 other locations
RM
Overseen byRoxana Mehran, MD, FACC
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Osprey Medical, Inc
No Placebo Group

Trial Summary

What is the purpose of this trial?

The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).

Research Team

RM

Roxana Mehran, MD, FACC

Principal Investigator

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Inclusion Criteria

The subject is a candidate for a therapeutic percutaneous coronary intervention (PCI) procedure.
The subject has documented chronic kidney disease (CKD)

Treatment Details

Interventions

  • AVERT (Contrast Media Volume Reduction Device)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Active TreatmentExperimental Treatment1 Intervention
Standard of Care with the AVERT system
Group II: Standard of CareActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Osprey Medical, Inc

Lead Sponsor

Trials
10
Recruited
10,900+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top